Mexiletine: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:
{{Mexiletine}}
{{Mexiletine}}


{{CMG}}; {{AE}} {{SS}]
{{CMG}}; {{AE}} {{SS}}


'''''For patient information about Mexiletine, click [[Mexiletine (patient information)|here]].'''''
'''''For patient information about Mexiletine, click [[Mexiletine (patient information)|here]].'''''
{{SB}} MEXILETINE HYDROCHLORIDE<sup>®</sup>
{{SB}} MEXILETINE HYDROCHLORIDE<sup>®</sup>
==Overview==
==Overview==

Revision as of 17:18, 3 March 2014


Mexiletine
MEXILETINE HYDROCHLORIDE® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Mexiletine
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

For patient information about Mexiletine, click here.

Synonyms / Brand Names: MEXILETINE HYDROCHLORIDE®

Overview

Mexiletine (INN, sold under the trade name Mexitil®) belongs to the Class IB anti-arrhythmic group of medicines. It is used to treat arrhythmias within the heart - or seriously irregular heartbeats. It slows nerve impulses in the heart and makes the heart tissue less sensitive. Dizziness, heartburn, nausea, nervousness, trembling, unsteadiness are common side effects. It is available in injection and capsule form.

Class IB antiarrhythmics decrease action potential duration by shortening the repolarization phase. This is achieved by blocking sodium channels[3].

Mexiletine may also be of use in patients experiencing refractory pain. (Sweetman, 2002) and is also effective for treating muscle stiffness resulting from myotonia congenita (Thomsen disease)

Category

Sodium channel blockers;Phenol ethers;Cardiovascular Drugs

FDA Package Insert

MEXILETINE HYDROCHLORIDE capsule

Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

Mexiletine hydrochloride is a local anesthetic, antiarrhythmic agent, structurally similar to lidocaine, but orally active. In animal studies, mexiletine has been shown to be effective in the suppression of induced ventricular arrhythmias, including those induced by glycoside toxicity and coronary artery ligation. Mexiletine, like lidocaine, inhibits the inward sodium current, thus reducing the rate of rise of the action potential, Phase 0. Mexiletine decreased the effective refractory period (ERP) in Purkinje fibers. The decrease in ERP was of lesser magnitude than the decrease in action potential duration (APD), with a resulting increase in the ERP/APD ratio.

References


Template:Antiarrhythmic agents